RIPK3-IN-3
Based on 1 Customer Validation
RIPK3-IN-3 (compound 20) is a selective inhibitor of RIP kinase RIPK3 (IC50=10 nM). RIPK3 mediates the phosphorylation of Mixed Lineage Kinase (MLKL) and causes necroptosis, while RIPK3-IN-3 inhibits p-MLKL oligomerization and thereby inhibits necroptosis. RIPK3-IN-3 also downregulates CXCL5 secretion and inhibits AsPC-1 cell migration and invasion.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 95.98%
- CAS No.: 3052303-53-1
- Formule: C16H11N5S
- Masse moléculaire:305.36
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
IC50: 10 nM (RIPK3)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HT-29 | CC50 |
>50 μM
Compound: 20
|
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability measured after 72 hrs by celltiter glo assay
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability measured after 72 hrs by celltiter glo assay
|
[PMID: 37494773] |
-
Cell Line:HT-29 cell
-
Concentration:10, 25, 50 μM
-
Incubation Time:2 h
-
Result:Inhibited phosphorylation of RIPK3 and MLKL in a concentration dependent manner.
-
Cell Line:U937 cells, HT-29cell
-
Concentration:20,50 μM
-
Incubation Time:2 h
-
Result:Decreased PI-positive cells to Hoechst-positive cells ratio.
Rescued the cell from the TCZ-induced cell necroptosis.
-
Cell Line:AsPC-1 cell
-
Concentration:20,50 μM
-
Incubation Time:24 h
-
Result:Suppressed migration capability of AsPC-1 pancreatic cancer cells in a dose dependent manner.
-
Cell Line:AsPC-1 cell
-
Concentration:20,50 μM
-
Incubation Time:2 h
-
Result:Suppressed invasion capability of AsPC-1 pancreatic cancer cells in a dose dependent manner.
-
Animal Model:TNF-induced SIRS model (C57BL/6 female mice)[1]
-
Dosage:10 or 25 mg/kg, single dose, TNFα (7 μg/mouse, iv)
-
Administration:Intraperitoneal injection (i.p.)
-
Result:Protects mice against lethal shock which is induced by TNFα and relieved the TNFα-induced temperature loss in a dose-dependent manner.
Decreases TNFα-induced IL-6 production in the mouse serum.
Chemical Information
-
CAS No. 3052303-53-1
-
Appearance Solid
-
Masse moléculaire 305.36
-
Formule C16H11N5S
-
Color Light yellow to yellow
-
SMILES
C=CC1=NC=C2N=CN=C(NC3=CC(N=CS4)=C4C=C3)C2=C1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
DMSO : 100 mg/mL (327.48 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.19 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (273 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2748 mL | 16.3741 mL | 32.7482 mL | 81.8706 mL |
| 5 mM | 0.6550 mL | 3.2748 mL | 6.5496 mL | 16.3741 mL | |
| 10 mM | 0.3275 mL | 1.6374 mL | 3.2748 mL | 8.1871 mL | |
| 15 mM | 0.2183 mL | 1.0916 mL | 2.1832 mL | 5.4580 mL | |
| 20 mM | 0.1637 mL | 0.8187 mL | 1.6374 mL | 4.0935 mL | |
| 25 mM | 0.1310 mL | 0.6550 mL | 1.3099 mL | 3.2748 mL | |
| 30 mM | 0.1092 mL | 0.5458 mL | 1.0916 mL | 2.7290 mL | |
| 40 mM | 0.0819 mL | 0.4094 mL | 0.8187 mL | 2.0468 mL | |
| 50 mM | 0.0655 mL | 0.3275 mL | 0.6550 mL | 1.6374 mL | |
| 60 mM | 0.0546 mL | 0.2729 mL | 0.5458 mL | 1.3645 mL | |
| 80 mM | 0.0409 mL | 0.2047 mL | 0.4094 mL | 1.0234 mL | |
| 100 mM | 0.0327 mL | 0.1637 mL | 0.3275 mL | 0.8187 mL |
RIPK3-IN-3 Related Classifications
HY-149393 Related Classifications
Powered by Bioz